912291-17-9

Usage

Benzylamine Group

A functional group consisting of an amine group (-NH2) bonded to a benzyl group (C6H5-CH2-).

Trifluoromethyl Substituent

A substituent containing three fluorine atoms (-CF3) attached to the 3-position of the benzylamine group.

Use in Research

Commonly used as an intermediate for the synthesis of other compounds in chemical and pharmaceutical research.

Chiral Building Block

Potential application as a chiral building block in organic synthesis, which is crucial for creating enantiomerically pure drugs and molecules.

Specific Properties and Functions

The unique structure and properties of 2-(3-TrifluoroMethyl-benzylaMino)-ethanol make it a valuable tool for various scientific and industrial applications.

Scientific and Industrial Applications

Due to its specific properties and functions, the compound can be used in a range of applications, including drug development, material science, and chemical synthesis.

Upstream product

• 1018908-98-9 C₁₀H₁₀F₃NO 
• 454-89-7 3-Trifluoromethylbenzaldehyde 
• 141-43-5 ethanolamine 

Downstream Products

• 1018909-04-0 tert-butyl 2-hydroxyethyl[3'-(trifluoromethyl)benzyl]carbamate 
• 1437110-50-3 9-nitro-4-(3-(trifluoromethyl)benzyl)-3,4,5,6-tetrahydro-2H-imidazo[2,1-b][1,3,6]oxadiazocine 
• 1437124-89-4 2-((2-((tert-butyldimethylsilyl)oxy)ethyl)(3-(trifluoromethyl)benzyl)amino)ethanol 

Relevant academic research and scientific papers

NITROIMIDAZOXADIAZOCINE COMPOUNDS

This invention relates to nitroimidazoxadiazocine compounds having the general Formula I, pharmaceutical compositions and uses of the same. The invention also relates to methods of making such nitroimidazoxadiazocine compounds of Formula I.

Discovery of highly potent and selective inhibitors of neuronal nitric oxide synthase by fragment hopping

Selective inhibition of neuronal nitric oxide synthase (nNOS) has been shown to prevent brain injury and is important for the treatment of various neurodegenerative disorders. This study shows that not only greater inhibitory potency and isozyme selectivity but more druglike properties can be achieved by fragment hopping. On the basis of the structure of lead molecule 6, fragment hopping effectively extracted the minimal pharmacophoric elements in the active site of nNOS for ligand hydrophobic and steric interactions and generated appropriate lipophilic fragments for lead optimization. More potent and selective inhibitors with better druglike properties were obtained within the design of 20 derivatives (compounds 7-26). Our structure - based inhibitor design for nNOS and SAR analysis reveal the robustness and efficiency of fragment hopping in lead discovery and structural optimization, which implicates a broad application of this approach to many other therapeutic targets for which known druglike small-molecule modulators are still limited.